10 important updates for Glioblastoma Awareness Day
Click Here to Manage Email Alerts
Today is Glioblastoma Awareness Day.
The second annual observance is intended to raise awareness about the importance of finding a cure for the disease, the most aggressive form of brain cancer. It also honors patients, families and caregivers, as well as the clinicians and researchers who are committed to helping those with glioblastoma.
In conjunction with the observance, HemOnc Today and Healio present the following updates in glioblastoma diagnosis and treatment.
• The FDA granted fast track designation to enzastaurin (DB102, Denovo Biopharma) for the treatment of patients with newly diagnosed glioblastoma. Read more.
• A newly opened clinical trial at City of Hope will evaluate chlorotoxin-directed chimeric antigen receptor T cells for treatment of brain tumors. Read more.
• Risk for suicide appeared higher among individuals within the first year of a brain cancer diagnosis compared with the general population. Read more.
• The FDA granted fast track designation to TVI-Brain-1 (TVAX Biomedical), an adoptive T cell therapy for the treatment of glioblastoma multiforme. Read more.
• Routine surveillance imaging after surgery did not appear to improve outcomes among patients with glioblastoma. Read more.
• Continued ofranergene obadenovec (VB-111, VBL Therapeutics) monotherapy priming after progression with bevacizumab (Avastin, Genentech) combination treatment improved survival outcomes among patients with recurrent glioblastoma, according to results of a phase 1/phase 2 study. Read more.
• Maximal resection of the contrast-enhanced tumor appeared associated with longer OS among all subgroups of patients with glioblastoma. Read more.
• An international study of glioblastoma revealed a cellular pathway that appears to contribute to glioma stem cell spread and proliferation. The findings put forth a new paradigm for glioma stem cell regulation, according to the researchers. Read more.
• Plasma cell-free DNA appeared to be an effective biomarker for tumor burden and a viable prognostic tool for disease progression among newly diagnosed patients with glioblastoma. Read more.
• Investigators from St. Michael’s Hospital and The Hospital for Sick Children in Toronto have determined that the transcriptional regulatory protein ID1 appears to maintain cancer stem cells in glioblastoma. Results suggest ID1 inhibition could lead to better treatment efficacy. Read more.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts